Letter | Published:

Cardiovascular and Metabolic Effects of Adenosine 3′,5′-Monophosphate in vivo

Naturevolume 207pages987988 (1965) | Download Citation



CATECHOLAMINES activate the enzyme, adenyl cyclase, which forms cyclic adenosine 3′,5′-monophosphate (3′,5′-AMP) in a variety of animal tissues1. This reaction system has been thought to control several metabolic processes, including glycogenolysis, steroidogenesis, keto-genesis, lipolysis and antidiuresis1–8. The positive ino-tropic and chronotropic effects of catecholamines on the heart are generally attributed to catechol interaction with the beta adrenergic receptor site. Rall and Sutherland2 and Mayer et al.9 have proposed that 3′, 5′-AMP might directly affect cardiac beta receptors by mediating hormone-induced changes in contractile force without necessarily involving glycogenolysis. During the course of investigations in the isolated perfused rat liver, 3′,5′-AMP was observed to induce delayed vasomotor changes unrelated to its glycogenolytic action10. This suggested that 3′, 5′-AMP might have a direct vascular effect on smooth muscle. Although 3′,5′-AMP produces hypergly-caemia in intact animals1,10–13, correlation of its metabolic action with possible regulation of cardiac activity has not been previously investigated.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Sutherland, E. W., and Rail, T. W., Pharmacol. Rev., 12, 265 (1960).

  2. 2

    Rall, T. W., and Sutherland, E. W., Cold Spring Harbor Symp., Quant Biol., 36, 347 (1961).

  3. 3

    Haynes, jun., R. C., Koritz, S. B., and Peron, F. G., J. Biol. Chem., 234, 1421 (1959).

  4. 4

    Hilton, J. G., Nedeljkovic, R. I., and Dermksian, G., Acta Endocrinol., Supp., 50, 705 (1960).

  5. 5

    Pryor, J., and Berthet, J., Biochim. Biophys. Acta, 43, 556 (1960).

  6. 6

    Rizak, M. A., J. Biol. Chem., 239, 392 (1964).

  7. 7

    Brown, E., Clarke, D. L., Roux, V., and Sherman, G. H., J. Biol. Chem., 238, PC 852 (1963).

  8. 8

    Orloff, J., and Handler, J. S., Biochem. Biophys. Res. Comm., 5, 63 (1961).

  9. 9

    Mayer, S. E., Cotton, M. Dev., and Moran, N. C., J. Pharmacol., 139, 275 (1963).

  10. 10

    Levine, R. A., Amer. J. Physiol., 208, 317 (1965).

  11. 11

    Posternak, T., Sutherland, E. W., and Henion, W. F., Biochim. Biophys. Acta, 65, 558 (1962).

  12. 12

    Northrop, G., Parks, jun., R. E., J. Pharmacol, 145, 135 (1964).

  13. 13

    Bergen, jun., S. S., Hilton, J. G., and Van Itallie, T. B., Clin. Res., 11, 214 (1963).

  14. 14

    Cawley, L. P., Spear, F. E., and Kendall, R., Amer. J. Clin. Path., 32, 195 (1959).

  15. 15

    Dole, V. P., J. Clin. Invest., 35, 150 (1956).

  16. 16

    Peterson, R. E., Wyngaarden, J. B., Guerra, S. L., Brodie, B. B., and Bunim, J. J., J. Clin. Invest., 34, 1779 (1955).

  17. 17

    Øye, I., Butcher, R. W., Morgan, H. E., and Sutherland, E. W., Fed. Proc., 23, 562 (1964).

Download references

Author information

Author notes


    Present address: Department of Medicine, Brooklyn-Cumberland Medical Center, 121 DeKalb Avenue, Brooklyn, New York


  1. U.S. Army Medical Research and Nutrition Laboratory, Fitzsimons General Hospital, Denver, Colorado

    •  & JAMES A. VOGEL


  1. Search for ROBERT A. LEVINE in:

  2. Search for JAMES A. VOGEL in:

About this article

Publication history

Issue Date



Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.